US 11083745
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
granted A61KA61K2300/00A61K31/712
Quick answer
US patent 11083745 (Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome) held by STOKE THERAPEUTICS, INC. expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- STOKE THERAPEUTICS, INC.
- Grant date
- Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 36
- CPC classes
- A61K, A61K2300/00, A61K31/712, A61K31/7125, A61K31/713